Cordis Corporation to Appeal Court Ruling

Miami (ots/PRNewswire) - Cordis Corporation, a Johnson & Johnsoncompany, today received a ruling from a court in the Netherlands thatfound the company infringed a Boston Scientific patent related to acatheter shaft that is used in the delivery system for the CYPHER(R)and CYPHER(R) Select Sirolimus-eluting Coronary Stents, as well asseveral other catheter-based products. Cordis intends to file anappeal with the Dutch Appeals Court.

The ruling requires that Cordis cease production of the ballooncatheters made at its facility in Roden, the Netherlands, whichsupplies CYPHER and CYPHER Select products for markets outside theUnited States, and to cease sales of these products in theNetherlands. The ruling does not prevent sales of these productsoutside of the Netherlands. Given current inventory and expandingmanufacturing capabilities elsewhere, Cordis does not expect asignificant impact on its ability to supply the ex-U.S. marketplacefor these products.

This ruling will not impact supply of the CYPHER Stent in theUnited States.

About Cordis Corporation

Cordis Corporation, a Johnson & Johnson company, is a worldwideleader in developing and manufacturing interventional vasculartechnology. Through research, development and innovation, physiciansworldwide are better able to treat the millions of patients whosuffer from vascular disease. For more information about Cordis,please visit http://www.cordis.com.

(This press release contains "forward-looking statements" asdefined in the Private Securities Litigation Reform Act of 1995.These statements are based on current expectations of future events.If underlying assumptions prove inaccurate or unknown risks oruncertainties materialize, actual results could vary materially fromthe Company's expectations and projections. Risks and uncertaintiesinclude general industry conditions and competition; economicconditions, such as interest rate and currency exchange ratefluctuations; technological advances and patents attained bycompetitors; challenges inherent in new product development,including obtaining regulatory approvals; domestic and foreign healthcare reforms and governmental laws and regulations; and trends towardhealth care cost containment. A further list and description of theserisks, uncertainties and other factors can be found in Exhibit 99(b)of the Company's Annual Report on Form 10-K for the fiscal year endedJanuary 2, 2005. Copies of this Form 10-K are available online athttp://www.sec.gov or on request from the Company. The Companyassumes no obligation to update any forward-looking statements as aresult of new information or future events or developments.)

For more information on Johnson & Johnson, please visit theCompany's website at http://www.jnj.com.

Web site: http://www.cordis.com http://www.jnj.com

ots Originaltext: Cordis Medizinische Apparate GmbHIm Internet recherchierbar: http://www.presseportal.de

Contact:Media: Terri Mueller, +1-786-313-8687, or Christopher Allman, +1-786-313-2303, or Investor: Helen Short, +1-732-524-6491, or Stan Panasewicz, +1-732-524-2524, all of Cordis Corporation

Cordis Medizinische Apparate GmbH

Zurück zur Übersiche Medizin-Nachrichten

Preisvergleich Medikamente
Medikament oder PZN:   
In Zusammenarbeit mit Medizinfuchs


Cordis Corporation to Appeal Court Ruling